Conventional high-throughput ‘chemical genetic’ screening seeks to identify small-molecule
inhibitors of a specific protein or pathway. A recent study describes how unbiased screening of
cellular morphology, followed by affinity purification to identify targets of compounds with
interesting effects, can lead to the identification of novel inhibitors.
